智通财经APP获悉,4月17日,国家药监局(NMPA)网站显示,葛兰素史克(GSK.US)的Belantamab mafodotin(玛贝兰妥单抗)在华获批上市。根据此前的优先审评信息,此次获批的适应症为联合硼替佐米和地塞米松治疗既往接受过至少一种治疗的多发性骨髓瘤成人患者。

玛贝兰妥单抗是Seagen(已被辉瑞收购)开发的一款BCMA ADC。2009年12月,GSK与Seagen达成协议,获得该药物的研究、开发、生产和商业化权益。
智通财经APP获悉,4月17日,国家药监局(NMPA)网站显示,葛兰素史克(GSK.US)的Belantamab mafodotin(玛贝兰妥单抗)在华获批上市。根据此前的优先审评信息,此次获批的适应症为联合硼替佐米和地塞米松治疗既往接受过至少一种治疗的多发性骨髓瘤成人患者。

玛贝兰妥单抗是Seagen(已被辉瑞收购)开发的一款BCMA ADC。2009年12月,GSK与Seagen达成协议,获得该药物的研究、开发、生产和商业化权益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.